Geode Capital Management, LLC Sage Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,191,331 shares of SAGE stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,191,331

Previous 1,167,257 2.06%

Holding current value

$12.9 Million

Previous $25.3 Million 11.74%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$18.62 - $26.95 $448,257 - $648,794	24,074 Added 2.06%	1,191,331 $22.3 Million
Q4 2023 Feb 13, 2024	BUY	$17.1 - $22.26 $1.06 Million - $1.37 Million	61,744 Added 5.59%	1,167,257 $25.3 Million
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $635,964 - $1.86 Million	37,968 Added 3.56%	1,105,513 $22.8 Million
Q2 2023 Aug 11, 2023	BUY	$40.65 - $59.54 $1.11 Million - $1.63 Million	27,300 Added 2.62%	1,067,545 $50.2 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $1.22 Million - $1.53 Million	32,815 Added 3.26%	1,040,245 $43.6 Million

Q4 2022 Feb 13, 2023	BUY	$32.2 - $43.61 $1.4 Million - $1.9 Million	43,476 Added 4.51%	1,007,430 $38.4 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $309,274 - $414,569	9,581 Added 1.0%	963,954 $37.7 Million
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $6.54 Million - $9.03 Million	237,691 Added 33.17%	954,373 $30.8 Million
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $5.88 Million - $8.76 Million	-191,547 Reduced 21.09%	716,682 $23.7 Million
Q4 2021 Feb 11, 2022	BUY	$37.06 - $47.11 $1.24 Million - $1.57 Million	33,424 Added 3.82%	908,229 $38.6 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $4.07 Million - $5.8 Million	101,121 Added 13.07%	874,805 $38.8 Million
Q2 2021 Aug 13, 2021	BUY	$54.88 - $79.29 $6.38 Million - $9.22 Million	116,220 Added 17.68%	773,684 $44 Million
Q1 2021 May 12, 2021	BUY	$70.65 - $96.76 $1.37 Million - $1.87 Million	19,377 Added 3.04%	657,464 $49.2 Million
Q4 2020 Feb 12, 2021	BUY	$58.41 - $89.06 $2.14 Million - $3.27 Million	36,687 Added 6.1%	638,087 $55.2 Million
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $781,470 - $1.19 Million	-19,000 Reduced 3.06%	601,400 $36.8 Million
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $652,850 - $1.09 Million	25,158 Added 4.23%	620,400 $25.8 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $619,362 - $1.83 Million	23,685 Added 4.14%	595,242 $17.1 Million
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $1.09 Million - $2.8 Million	18,067 Added 3.26%	571,557 $41.3 Million
Q3 2019 Nov 12, 2019	BUY	$140.29 - $189.96 $984,555 - $1.33 Million	7,018 Added 1.28%	553,490 $77.6 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $3.42 Million - $3.97 Million	21,686 Added 4.13%	546,472 $100 Million
Q1 2019 May 14, 2019	BUY	$89.33 - $163.65 $5.08 Million - $9.31 Million	56,869 Added 12.15%	524,786 $83.5 Million
Q4 2018 Feb 13, 2019	BUY	$81.94 - $139.71 $2.62 Million - $4.48 Million	32,033 Added 7.35%	467,917 $44.8 Million
Q3 2018 Nov 13, 2018	BUY	$138.11 - $169.04 $90,185 - $110,383	653 Added 0.15%	435,884 $61.6 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $1.03 Million - $1.29 Million	7,357 Added 1.72%	435,231 $68.1 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $7.15 Million - $9.04 Million	46,978 Added 12.33%	427,874 $68.9 Million
Q4 2017 Feb 13, 2018	BUY	$60.72 - $167.34 $4.42 Million - $12.2 Million	72,790 Added 23.62%	380,896 $62.7 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $916,210 - $1.32 Million	14,922 Added 5.09%	308,106 $19.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	293,184	293,184 $23.3 Million

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $643M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Sage Therapeutics, Inc. Transaction History